View:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. __)*
Neurocrine Biosciences, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, no par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
64125C10
-----------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 pages
- --------------------------------------------------------------------------------
CUSIP NO. 64125C10 13G PAGE 2 OF 5 PAGES
----- -----
- --------------------------------------------------------------------------------
- ------- ------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Abingworth Bioventures SICAV
- ------- ------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
- ------- ------------------------------------------------------------------------
3 SEC USE ONLY
- ------- ------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
- ------------------------- ----- ------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
878,970
----- ------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY - 0 -
----- ------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 878,970
----- ------------------------------------------------
WITH 8 SHARED DISPOSITIVE POWER
- 0 -
- ------- ------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
878,970
- ------- ------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*[ ]
- ------- ------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.2%
- ------- ------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
CO
- ------- ------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 5 pages
ITEM 1(A). Name of Issuer: Neurocrine Biosciences, Inc.
ITEM 1(B). Address of Issuer's Principal Executive Offices:
3050 Science Park Road, San Diego, CA 92121
ITEM 2(A). Name of Person Filing: Abingworth Bioventures SICAV ("ABS")
ITEM 2(B). Address of Principal Business Office or, if None, Residence:
The address of the principal business office of ABS is 231 Val
des Bons Malades, L-2121 Luxembourg-Kirchberg.
ITEM 2(C). Citizenship: ABS is a corporation organized under the laws of
Luxembourg.
ITEM 2(D). Title of Class of Securities: Common Stock, no par value.
ITEM 2(E). CUSIP Number: 64125C10
ITEM 3. If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b), check whether the person filing is a:
(a) [ ] Broker or Dealer registered under Section 15 of
the Securities Exchange Act of 1934 (the "Act").
(b) [ ] Bank as defined in Section 3(a)(6) of the Act.
(c) [ ] Insurance Company as defined in Section 3(a)(19) of
the Act.
(d) [ ] Investment Company registered under Section 8 of
the Investment Company Act of 1940.
(e) [ ] Investment Adviser registered under Section 203 of
the Investment Advisers Act of 1940.
(f) [ ] Employee Benefit Plan, Pension Fund which is
subject to the provisions of the Employee
Retirement Income Security Act of 1974 or Endowment
Fund; see Rule 13d-1(b)(1)(ii)(F) of the Act.
(g) [ ] Parent Holding Company, in accordance with Rule
13d-1(b)(ii)(G) of the Act.
(h) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(H)of
the Act.
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b) or Rule13d-2(b).
Page 3 of 5 pages
ITEM 4. Ownership.
(a) Amount Beneficially Owned: ABS is the record and
beneficial owner of 878,970 shares of Common Stock as
of December 31, 1996.
(b) Percent of Class: 5.2%. The foregoing percentage is
calculated based on the 16,766,473 shares of Common
Stock reported to be outstanding in the Quarterly
Report on Form 10-Q of Neurocrine Biosciences, Inc.
for the quarter ended September 30, 1996.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
878,970 shares.
(ii) shared power to vote or to direct the vote:
0 shares.
(iii) sole power to dispose or to direct the
disposition of: 878,970 shares.
(iv) shared power to dispose or to direct the
disposition of: 0 shares.
ITEM 5. Ownership of Five Percent or Less of a Class.
Not applicable.
ITEM 6. Ownership of More than Five Percent on Behalf of Another
Person.
Not applicable.
ITEM 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company.
Not applicable.
ITEM 8. Identification and Classification of Members of the Group.
Not applicable
ITEM 9. Notice of Dissolution of Group.
Not applicable.
ITEM 10. Certification.
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b).
Page 4 of 5 pages
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: February 4, 1997
ABINGWORTH BIOVENTURES SICAV
By: /s/ Karl U. SANNE
----------------------
Name: Karl U. SANNE
Title: Director
By: /s/ Fernand HEIM
----------------------
Name: Fernand HEIM
Title: Mandatory